Affinage

PRMT7

Protein arginine N-methyltransferase 7 · UniProt Q9NVM4

Length
692 aa
Mass
78.5 kDa
Annotated
2026-06-10
78 papers in source corpus 39 papers cited in narrative 39 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 7/7 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

PRMT7 is the sole mammalian type III protein arginine methyltransferase, catalyzing S-adenosylmethionine-dependent formation of ω-NG-monomethylarginine exclusively, with no asymmetric or symmetric dimethylation activity on the substrates and conditions tested (PMID:15044439, PMID:22241471, PMID:24247247). Its catalytic competence depends on tandem duplicated AdoMet-binding domains, both of which are required because single-domain truncations are inactive (PMID:15044439), and on active-site residues including Glu-478 and the double-E-loop residues Asp-147/Glu-149 that set both activity and substrate preference (PMID:24247247, PMID:25294873); it selectively methylates arginines within RXR motifs flanked by basic residues, a preference governed primarily by Vmax rather than substrate affinity (PMID:24247247, PMID:37216364). Through these monomethylation events PRMT7 acts on both chromatin and a broad set of non-histone substrates to control diverse programs. On chromatin it deposits H4R3 and H3R2 methyl marks to repress or activate target loci, repressing E-cadherin during breast cancer EMT via recruitment of YY1 and HDAC3 (PMID:25136067) and activating Foxm1, HMGB2, and PTEN transcription through promoter H4R3me1/H3R2me1 marks (PMID:34497269, PMID:38376246, PMID:40243588). As a non-histone modifier it methylates signaling and stress-response proteins to reprogram their activity: it monomethylates MAVS (R52, R232) to dampen RIG-I-dependent antiviral signaling, with viral infection triggering PRMT7 automethylation and SMURF1-mediated degradation to relieve this brake (PMID:34171297, PMID:39546576); methylates HSP70 at R469 in an ATP-dependent open conformation to support proteostasis and stress tolerance (PMID:32409666); methylates eIF2α to enable stress-granule formation (PMID:30699057); activates p38MAPKα (R70) to drive MyoD-dependent myogenesis and PGC-1α-dependent oxidative metabolism (PMID:27207521, PMID:31243342); methylates GLI2 (R225/227) to release SUFU inhibition and promote Hedgehog signaling (PMID:31000813); and methylates β-catenin to modulate Wnt output (PMID:35089423). PRMT7 governs stem-cell self-renewal and metabolism, acting upstream of a DNMT3b/p21 axis in muscle satellite cells (PMID:26854227) and reprogramming glycine metabolism in chronic myeloid leukemia stem cells (PMID:35508169). Its activity is itself controlled by AKT1 phosphorylation at Thr-73 and stimulated by CTCFL/BORIS during genomic imprinting (PMID:17048991, PMID:41876450). Human homozygous loss of the PRMT7 transcription start site reduces histone H2B/H4 arginine methylation and perturbs Wnt signaling in patient cells (PMID:27718516).

Mechanistic history

Synthesis pass · year-by-year structured walk · 11 steps
  1. 2004 High

    Established PRMT7 as an active arginine methyltransferase and showed that its duplicated AdoMet-binding architecture is functionally obligatory, defining the enzyme's basic catalytic requirement.

    Evidence In vitro methylation of RGG-motif peptides with GST-PRMT7 plus domain-truncation mutagenesis and product identification

    PMID:15044439 PMID:15494416

    Open questions at the time
    • Early reports of symmetric dimethylation product were not reconciled with later type III-only findings
    • physiological substrates not yet identified
    • no structural basis for two-domain cooperation
  2. 2006 High

    Linked PRMT7 to chromatin and genomic imprinting by showing CTCFL/BORIS stimulates its histone methyltransferase activity and that the complex can establish H19 ICR methylation, placing PRMT7 in an epigenetic regulatory context.

    Evidence Co-IP, ChIP for H4R3me2s, and Xenopus oocyte reconstitution with CTCFL/PRMT7/Dnmt3a/b/L

    PMID:17048991

    Open questions at the time
    • Direct enzymatic product on H19 chromatin not isolated
    • mechanism by which CTCFL stimulates activity unresolved
    • single-lab finding
  3. 2012 High

    Resolved the catalytic class of PRMT7 as a strict type III enzyme producing only monomethylarginine, correcting earlier dimethylation claims and constraining all downstream mechanism.

    Evidence In vitro methylation across multiple substrates and conditions with PRMT1/PRMT5 controls

    PMID:22241471

    Open questions at the time
    • Does not explain in-cell H4R3me2s observations attributed to PRMT7
    • substrate spectrum in vivo not defined
  4. 2013 High

    Defined PRMT7 substrate selectivity (RXR motifs in basic context, H2B preferred) and the active-site residues controlling catalysis, providing the structural logic for substrate choice.

    Evidence Recombinant enzyme assays, site-directed mutagenesis of double-E loop and Glu-478, and MS site mapping

    PMID:24247247 PMID:25294873

    Open questions at the time
    • Co-crystal structure with substrate not reported
    • unusual sub-37°C temperature optimum biological meaning unclear
  5. 2016 High

    Demonstrated that PRMT7 controls stem cell self-renewal and oxidative metabolism in vivo, positioning it upstream of a DNMT3b/p21 senescence axis and a p38MAPK/ATF2/PGC-1α metabolic axis.

    Evidence Conditional and whole-body Prmt7 knockout mice with regeneration assays, DNMT3b epistasis rescue, Co-IP and reporter assays

    PMID:26854227 PMID:27207521

    Open questions at the time
    • Direct methylation substrate driving senescence not pinpointed in 2016
    • p38MAPK activation mechanism (later mapped to R70) not yet established
  6. 2016 Medium

    Connected PRMT7 to human disease, showing biallelic loss reduces histone H2B/H4 arginine methylation and alters Wnt signaling in patient cells.

    Evidence Patient-derived cells with homozygous TSS deletion, methylation assays, Wnt reporter

    PMID:27718516

    Open questions at the time
    • Single patient study
    • molecular link from methylation loss to Wnt phenotype not mechanistically traced
  7. 2019 High

    Expanded PRMT7 into a non-histone signaling modifier by identifying specific methylation sites that toggle protein activity — p38MAPKα-R70, GLI2-R225/227, eIF2α, and β-catenin — connecting it to myogenesis, Hedgehog, stress granules, and Wnt.

    Evidence In vitro methylation with site identification, site-directed mutagenesis, ChIP, reporter assays, KO MEFs, and stress-granule imaging across studies

    PMID:30699057 PMID:31000813 PMID:31243342 PMID:31371025

    Open questions at the time
    • Whether each modification occurs at physiological stoichiometry not quantified
    • structural basis for site recognition in folded substrates unresolved
  8. 2020 High

    Showed PRMT7 reads substrate conformation (ATP-bound open HSP70) and that its non-histone marks reorganize protein complexes, methylating SHANK2-R240 to activate endosomal FAK/cortactin signaling, broadening its role to proteostasis and metastatic signaling.

    Evidence Structural analysis with conformation-specific HSP70 methylation, chemical-probe and KO validation; SHANK2 R240 mutagenesis, endosomal fractionation, and xenograft assays

    PMID:32409666 PMID:32844749

    Open questions at the time
    • How conformational selectivity is encoded in the active site not fully defined
    • in vivo HSP70 methylation stoichiometry under stress not measured
  9. 2021 High

    Established PRMT7 as a negative regulator of antiviral innate immunity through MAVS-R52 monomethylation, with a built-in infection-triggered shut-off via automethylation and SMURF1-dependent degradation.

    Evidence In vitro methylation, site mutagenesis, Co-IP, PRMT7 KO cells and mice, viral infection assays

    PMID:34171297

    Open questions at the time
    • Functional role of PRMT7 aggregation in catalysis unclear
    • trigger linking infection to automethylation not defined
  10. 2022 High

    Tied PRMT7-deposited histone marks to disease-relevant transcriptional programs (RAP1A in COPD monocytes, ERV silencing in melanoma immune evasion) and to metabolic vulnerability of leukemia stem cells via glycine metabolism reprogramming.

    Evidence Conditional KO mice, ChIP for H4R3me1/H4R3me2s, bisulfite sequencing, metabolomics, and in vivo tumor/disease models

    PMID:35288557 PMID:35354055 PMID:35508169

    Open questions at the time
    • Direct substrate(s) linking PRMT7 to DNMT expression not identified
    • whether glycine metabolism effect is histone- or non-histone-mediated unresolved
  11. 2024 High

    Refined upstream and downstream control of PRMT7: AKT1 phosphorylates it at T73 to boost activity toward GLUD1-R76, ROCK1 phosphorylation creates phospho-methyl crosstalk on formin DAD domains, and a second MAVS site (R232) was validated by knock-in mice and a peptide inhibitor.

    Evidence In vitro phosphorylation/methylation assays, sequential-PTM competition, MAVS R232K knock-in mice with VSV challenge, and peptide inhibitor design

    PMID:39368550 PMID:39546576 PMID:41876450

    Open questions at the time
    • Integration of multiple regulatory inputs in a single cell not modeled
    • kinetics of phospho-methyl competition in vivo not measured

Open questions

Synthesis pass · forward-looking unresolved questions
  • A unified structural and quantitative framework explaining how a single monomethyl mark on dozens of histone and non-histone substrates produces context-specific outcomes — and which substrates dominate in each tissue — remains unresolved.
  • No substrate co-crystal structure defining RXR-motif recognition in folded proteins
  • relative in vivo flux through histone vs non-histone substrates unquantified
  • rules governing which downstream pathway dominates per cell type unknown

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140096 catalytic activity, acting on a protein 6 GO:0042393 histone binding 4 GO:0016740 transferase activity 3
Localization
GO:0005634 nucleus 3 GO:0005829 cytosol 3
Pathway
R-HSA-1266738 Developmental Biology 4 R-HSA-162582 Signal Transduction 4 R-HSA-74160 Gene expression (Transcription) 4 R-HSA-1430728 Metabolism 3 R-HSA-168256 Immune System 3 R-HSA-392499 Metabolism of proteins 2
Partners
ASS1CTCFLEIF2AGLI2HSP70MAVSPTENSHANK2

Evidence

Reading pass · 39 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2004 PRMT7 is a protein arginine methyltransferase that catalyzes S-adenosylmethionine-dependent monomethylation of arginine residues in peptides containing RGG motifs; both putative AdoMet-binding domains (arising from gene duplication) are required for activity, as truncated single-domain proteins are enzymatically inactive. In vitro methylation assay with GST-PRMT7 fusion protein, HPLC purification, cation-exchange chromatography of hydrolysis products; domain truncation mutagenesis The Journal of biological chemistry High 15044439
2004 PRMT7 expressed in E. coli and mammalian cells methylates histones, myelin basic protein, fibrillarin GAR fragment, and SmB, producing predominantly monomethylarginine and symmetric dimethylarginine (SDMA); a GRG tripeptide motif is sufficient for symmetric dimethylation. Immunopurified PRMT7, in vitro methylation assay, amino acid analysis The Journal of biological chemistry Medium 15494416
2006 PRMT7 interacts with CTCFL/BORIS and is expressed in embryonic testis coinciding with H19 ICR methylation timing; CTCFL stimulates PRMT7 histone methyltransferase activity through interactions with both histones and PRMT7; H4R3me2s (symmetric) accumulates at H19 ICR and Gtl2 DMR chromatin in testis; co-injection of CTCFL, PRMT7, and Dnmt3a/b/L in Xenopus oocytes establishes H19 ICR methylation. Co-immunoprecipitation, ChIP, in vitro histone methyltransferase assay, Xenopus oocyte nuclear injection PLoS biology High 17048991
2012 Human PRMT7 is a type III enzyme that exclusively produces ω-NG-monomethylarginine under all tested conditions; it does not produce asymmetric or symmetric dimethylarginine on peptides, GST-GAR, myelin basic protein, or histones H2A–H4. In vitro methylation assay with GST-PRMT7, multiple substrates and conditions; comparison with PRMT1 and PRMT5 controls The Journal of biological chemistry High 22241471
2013 Mouse PRMT7 expressed in insect cells is a type III monomethylarginine-only enzyme; histone H2B is a highly preferred substrate; PRMT7 preferentially methylates arginine residues within RXR motifs surrounded by basic residues; Asp-147 and Glu-149 in the double E loop modulate substrate preference, and Glu-478 mutation nearly abolishes activity. Recombinant protein purification, in vitro methylation assay with multiple substrates, site-directed mutagenesis, mass spectrometry identification of methylation sites The Journal of biological chemistry High 24247247
2014 PRMT7 promotes EMT and metastasis in breast cancer by binding to the E-cadherin proximal promoter and elevating H4R3me2s and reducing H3K4me3 and histone acetylation; PRMT7 interacts with YY1 and HDAC3 and recruits them to the E-cadherin promoter to repress its expression. ChIP, Co-IP, siRNA knockdown, cell migration/invasion assays Cancer research Medium 25136067
2014 Acidic residues Asp-147 and Glu-149 in the double E loop of PRMT7 modulate substrate preference, and Glu-478 in the C-terminal domain is essential for catalytic activity; PRMT7 shows unusual temperature dependence with optimum well below 37°C. Site-directed mutagenesis, in vitro methylation assay with GST-PRMT7 fusion The Journal of biological chemistry High 25294873
2015 PRMT7 and PRMT5 share a cofactor-binding site; DS-437, designed using PRMT5 structural information, inhibits both PRMT5 (IC50 6 µM) and PRMT7 with the same potency, acting as a cofactor competitor, suggesting a common SAM-binding scaffold. Biochemical inhibition assay, selectivity panel against 29 methyltransferases, cellular SDMA inhibition assay ACS medicinal chemistry letters Medium 25893041
2015 PRMT7 represses the miR-24-2 gene in mouse ESCs by increasing H4R3me2s levels at its locus; depletion of PRMT7 reduces H4R3me2s, de-represses miR-24-3p and miR-24-2-5p, which in turn suppress Oct4, Nanog, Klf4, and c-Myc to promote differentiation. ChIP, reporter assays, RNA-seq, PRMT7 depletion and anti-miRNA rescue in mouse ESCs Nucleic acids research Medium 27625395
2015 In B cells, PRMT7 recruits H4R3me1 and symmetric H4R3me2 to the Bcl6 promoter, negatively regulating Bcl6 expression; B cell-specific PRMT7 knockout mice show decreased marginal zone B cells, promoted germinal center formation, and altered Bcl6, Prdm1, and Irf4 expression. Conditional knockout mice, ChIP-PCR, overexpression in lymphoma cell lines Journal of immunology Medium 26179907
2016 PRMT7 deficiency in satellite cells causes cell-cycle arrest and premature cellular senescence with elevated p21CIP1 and decreased DNMT3b; restoration of DNMT3b in PRMT7-deficient cells rescues senescence, placing PRMT7 upstream of DNMT3b/p21 axis in muscle stem cell self-renewal. Conditional knockout (Pax7-CreERT2), muscle injury/regeneration assays, epistasis by DNMT3b rescue Cell reports High 26854227
2016 PRMT7 regulates skeletal muscle oxidative metabolism by interacting with and activating p38MAPK, which in turn activates ATF2 to transcriptionally upregulate PGC-1α; Prmt7-/- muscles show reduced oxidative metabolism, PGC-1α expression, and exercise capacity. Prmt7 knockout mice, Co-IP, reporter assays, siRNA depletion in myoblasts Diabetes Medium 27207521
2016 PRMT7 loss-of-function in humans (homozygous deletion of transcription start site) causes decreased protein arginine methylation of histones H2B and H4, and the resulting patient cells show altered Wnt signaling. Patient-derived cells, methylation assays, Wnt pathway reporter Clinical genetics Medium 27718516
2017 PRMT7 directly interacts with argininosuccinate synthetase 1 (ASS1) via pull-down; citrullinemia type I mutations in ASS1 disrupt this interaction; evolutionary co-analysis supports co-evolution of interacting residues. Yeast two-hybrid screen, pull-down assay, site-directed mutagenesis, computational interface mapping Journal of molecular biology Medium 28587924
2018 PRMT7 promotes epiboly and gastrulation cell movements in zebrafish by facilitating syntenin; PRMT7 regulates F-actin organization in the enveloping layer and yolk syncytial layer; rescue experiments with either Prmt7 or syntenin re-expression restore normal epiboly. Morpholino knockdown in zebrafish, rescue by mRNA injection, F-actin staining Acta biochimica et biophysica Sinica Medium 30383201
2019 PRMT7 methylates p38MAPKα at arginine residue 70, promoting its activation, which enhances MyoD activities; the R70A mutation in p38MAPKα impedes MyoD/E47 heterodimerization and recruitment of Prmt7, MyoD, and Baf60c to the Myogenin promoter, blunting Myogenin expression. In vitro methylation assay identifying R70, site-directed mutagenesis (R70A), ChIP, Co-IP, differentiation assays Cell death and differentiation High 31243342
2019 PRMT7 promotes Sonic Hedgehog signaling by methylating GLI2 at arginine residues 225 and 227 near its SUFU-binding region; this methylation reduces GLI2-SUFU interaction, leading to increased GLI2 nuclear accumulation and Shh target gene activation, suppressing cellular senescence. Co-IP, in vitro methylation assay, site-directed mutagenesis, GLI2 reporter assay, PRMT7 KO MEFs Cell death and differentiation High 31000813
2019 PRMT7 interacts with and methylates eIF2α in vitro and in breast cancer cells; PRMT7-mediated arginine methylation of eIF2α regulates its phosphorylation status at serine 51; PRMT7 is required for eIF2α-dependent stress granule formation under various cellular stresses. Quantitative MS interactome, in vitro methylation assay, stress granule imaging, siRNA knockdown Molecular biology of the cell Medium 30699057
2019 PRMT7 interacts with and methylates C/EBP-β upon adipogenic induction; PRMT7 depletion increases adipogenesis and promotes mitotic clonal expansion; PRMT7 modulates C/EBP-β accumulation at PPAR-γ2 promoter target sites. Co-IP, ChIP, PRMT7 KO MEFs, adipogenesis assays Biochemical and biophysical research communications Medium 31371025
2020 PRMT7 drives methylation of HSP70 at R469 in vitro; this methylation requires an ATP-bound, open conformation of HSP70; pharmacological inhibition or knockout of PRMT7 drastically reduces arginine monomethylation of HSP70 family proteins and decreases cellular tolerance to heat shock and proteasome inhibitors. Crystal structure/structural analysis, in vitro methylation assay with conformation-specific HSP70, PRMT7 inhibitor (SGC3027/SGC8158), PRMT7 KO cells Nature communications High 32409666
2020 PRMT7 methylates SHANK2 at R240, causing di-methylation that disrupts the SPN-ANK domain blockade of SHANK2 and promotes co-accumulation of dynamin2, talin, FAK, and cortactin on endosomes, activating endosomal FAK/cortactin signaling to promote breast cancer metastasis. In vitro methylation assay, site-directed mutagenesis (R240), endosomal fractionation, Co-IP, cell migration/invasion assays, xenograft model eLife High 32844749
2020 PRMT7 upregulates C-MYC expression in renal cell carcinoma by methylating β-catenin, inhibiting its ubiquitin-mediated degradation and thereby activating β-catenin/C-MYC signaling to promote cell proliferation. Co-IP, ubiquitination assay, siRNA/overexpression, methyltransferase inhibitor (Adox), xenograft model The international journal of biochemistry & cell biology Medium 31926310
2021 PRMT7 forms aggregates to catalyze MAVS monomethylation at R52, attenuating MAVS binding to TRIM31 and RIG-I and suppressing MAVS aggregation and antiviral signaling; upon viral infection, PRMT7 undergoes automethylation at R32, SMURF1 is recruited to PRMT7 by MAVS, and PRMT7 is targeted for proteasomal degradation, relieving suppression of antiviral defense. In vitro methylation assay, site-directed mutagenesis, Co-IP, PRMT7 KO cells and mice, viral infection assays Molecular cell High 34171297
2021 PRMT7 catalyzes H4R3me1 at the Foxm1 gene promoter to activate Foxm1 transcription, regulating cell cycle genes and thereby controlling alveolar myofibroblast proliferation and differentiation during lung alveologenesis. ChIP, PRMT7 KO mice, Foxm1 overexpression rescue, myofibroblast isolation Cell death & disease Medium 34497269
2022 In COPD, NF-κB/RelA activation in monocytes induces PRMT7 transcription, which leads to H4R3me1 at the RAP1A gene locus, increasing RAP1A transcription and promoting monocyte adhesion and migration; persistent monocyte-derived macrophage accumulation causes ALOX5/LTB4 overproduction and ACSL4-mediated ferroptosis in lung epithelial cells. Conditional PRMT7 KO mice, ChIP, NF-κB pathway analysis, COPD patient tissue analysis, lung fibrosis and skin injury models Nature communications High 35288557
2022 Loss of PRMT7 in CML reduces expression of glycine decarboxylase, reprogramming glycine metabolism to generate methylglyoxal, which is detrimental specifically to leukemia stem cells; genetic Prmt7 deletion or pharmacological PRMT7 inhibition selectively impairs CML LSC self-renewal without affecting normal hematopoiesis. Prmt7 genetic KO in CML mouse model, specific PRMT7 inhibitor, primary CML CD34+ cells, metabolomics Cell metabolism High 35508169
2022 PRMT7 deficiency in B16.F10 melanoma reduces DNMT expression and causes loss of DNA methylation at endogenous retroviral element (ERV) regulatory regions, increasing ERV expression and activating dsRNA sensing by RIG-I and MDA5; H4R3me2s is reduced at RIG-I and MDA5 promoters in PRMT7-deficient cells. PRMT7 KO and inhibitor (SGC3027), bisulfite sequencing, ChIP, RNA-seq, in vivo tumor growth with immune checkpoint blockade Cell reports Medium 35354055
2022 PRMT7 deficiency in cardiomyocytes decreases symmetric dimethylation of β-catenin at arginine 93, resulting in enhanced β-catenin activity and Wnt signaling, leading to cardiac hypertrophy and fibrosis. Cardiomyocyte-specific PRMT7 KO mice, in vitro methylation assay identifying R93 on β-catenin, β-catenin activity assays, cardiac transcriptome analysis Cellular and molecular life sciences Medium 35089423
2022 PRMT7-mediated histone arginine monomethylation regulates RUNX1 target gene expression in T-ALL; CRISPR deletion of PRMT7 changes arginine monomethylation patterns in protein complexes associated with RNA/DNA processing including RUNX1. CRISPR-Cas9 KO, proteomic arginine methylation profiling, colony formation assay Cancers Medium 35565298
2023 PRMT7 methylates PTEN, promoting its arginine methylation; PRMT7 enhances PTEN transcription by increasing H3R2me1 at the PTEN promoter; PRMT7 interacts with PTEN protein and stabilizes nuclear PTEN; PRMT7 inhibits PI3K/AKT signaling in gastric cancer through PTEN regulation. Co-IP, ChIP, in vitro methylation, PRMT7 overexpression/knockdown, PI3K/AKT signaling readouts Journal of Cancer Medium 37781082
2024 PRMT7 methylates MAVS at arginine R232 (R232me1), reducing MAVS/RIG-I interaction and MAVS aggregation; RNA virus infection downregulates PRMT7 and decreases R232me1, enhancing MAVS/RIG-I interaction and antiviral signaling; knock-in mice with MAVS R232K substitution are more resistant to VSV infection; a peptide inhibitor of PRMT7-MAVS interaction (PiPRMT7-MAVS) suppresses R232me1 and enhances antiviral immunity. In vitro methylation assay, MAVS R232K knock-in mice, VSV infection, Co-IP, peptide inhibitor design Proceedings of the National Academy of Sciences of the United States of America High 39546576
2024 PRMT7 activates HLH-30/TFEB nuclear transactivation in C. elegans by methylating HLH-30 on its RAG complex binding domain, facilitating nuclear localization; this function is evolutionarily conserved in human TFEB and intestinal cells responding to bacterial pore-forming toxins. C. elegans genetics (prmt-7 mutants), in vitro methylation, TFEB localization assays in human intestinal cells Autophagy Medium 38261662
2024 PRMT7 catalyzes H4R3me1 at the HMGB2 promoter to activate HMGB2 transcription; HMGB2 then facilitates ACSL1 transcription, promoting ferroptosis; inhibition of PRMT7 suppresses the HMGB2-ACSL1 ferroptosis pathway in pancreatitis. ChIP, overexpression/KO, ferroptosis assays, PRMT7 inhibitor in SAP model Journal of proteome research Medium 38376246
2024 AKT1 phosphorylates PRMT7 at threonine 73 (T73), promoting PRMT7 activity; phosphorylated PRMT7 monomethylates GLUD1 at R76, stabilizing GLUD1 by antagonizing ubiquitin-dependent degradation, thereby enhancing glutamine metabolism and gastric cancer progression. In vitro phosphorylation and methylation assays, site-directed mutagenesis, Co-IP, ubiquitination assay, xenograft model Cell death & disease Medium 41876450
2024 PRMT7 promotes osteogenic differentiation of mesenchymal stem cells by increasing H3R2me1 levels at the PTEN promoter to enhance PTEN transcription; PRMT7 also interacts with PTEN protein and stabilizes nuclear PTEN by preventing its ubiquitination and degradation; female-specific conditional Prmt7 KO impairs osteogenesis, rescued by PTEN overexpression. Conditional KO mice (female-specific phenotype), ChIP, Co-IP, ubiquitination assay, PTEN rescue experiments International journal of molecular sciences Medium 40243588
2024 PRMT7 methylates Fhod1 and Fhod3 (formin homology domain proteins) at arginine residues in the diaphanous autoinhibitory domain (DAD), specifically R1588 and/or R1590 of Fhod3 isoform 4; prior phosphorylation of S1589 by ROCK1 prevents subsequent PRMT7 methylation of R1588/R1590, revealing phosphorylation-methylation crosstalk on the DAD domain. In vitro methylation assay, in vitro ROCK1 phosphorylation assay, site-directed mutagenesis, sequential PTM competition assay The Journal of biological chemistry High 39368550
2024 PRMT7 controls JAK/STAT signaling in cardiomyocytes by regulating expression of SOCS3, a negative feedback inhibitor of JAK/STAT; Prmt7 cardiac KO leads to dysregulated JAK/STAT signaling; 17β-estradiol attenuates doxorubicin-induced decreases in PRMT7 expression, and PRMT7 depletion abrogates estrogen's cardioprotective effect. Cardiac-specific KO mice, transcriptome analysis, cardiomyocyte-specific siRNA, E2 treatment Experimental & molecular medicine Medium 38486105
2023 PRMT7 substrate recognition of RXR motifs is primarily determined by differences in Vmax rather than apparent Km; even subtle substitutions (e.g., K30R and R31K) in the RXR context of histone H2B greatly reduce methylation; ionic strength reduces PRMT7 activity mainly by increasing apparent Km. In vitro methylation kinetics with synthetic peptides and full-length histones, Xenopus laevis H2B substitution variants PloS one Medium 37216364
2019 In Leishmania, PRMT7 is a cytoplasmic protein that methylates RNA-binding proteins Alba3 and RBP16; PRMT7-dependent methylation promotes Alba3 association with specific target transcripts including δ-amastin mRNA, thereby stabilizing this virulence factor transcript; PRMT7 KO reduces RNA-binding capacity of Alba3 and affects RBP16 protein stability. Comparative methyl-SILAC proteomics, in vitro methylation assay, RNA immunoprecipitation, PRMT7 KO in Leishmania Nucleic acids research Medium 32365184

Source papers

Stage 0 corpus · 78 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2012 Human protein arginine methyltransferase 7 (PRMT7) is a type III enzyme forming ω-NG-monomethylated arginine residues. The Journal of biological chemistry 209 22241471
2004 PRMT7 is a member of the protein arginine methyltransferase family with a distinct substrate specificity. The Journal of biological chemistry 172 15044439
2004 PRMT7, a new protein arginine methyltransferase that synthesizes symmetric dimethylarginine. The Journal of biological chemistry 166 15494416
2006 The testis-specific factor CTCFL cooperates with the protein methyltransferase PRMT7 in H19 imprinting control region methylation. PLoS biology 162 17048991
2013 Mammalian protein arginine methyltransferase 7 (PRMT7) specifically targets RXR sites in lysine- and arginine-rich regions. The Journal of biological chemistry 143 24247247
2014 PRMT7 induces epithelial-to-mesenchymal transition and promotes metastasis in breast cancer. Cancer research 119 25136067
2022 The arginine methyltransferase PRMT7 promotes extravasation of monocytes resulting in tissue injury in COPD. Nature communications 110 35288557
2016 Prmt7 Deficiency Causes Reduced Skeletal Muscle Oxidative Metabolism and Age-Related Obesity. Diabetes 84 27207521
2015 Discovery of a Dual PRMT5-PRMT7 Inhibitor. ACS medicinal chemistry letters 82 25893041
2020 Pharmacological inhibition of PRMT7 links arginine monomethylation to the cellular stress response. Nature communications 80 32409666
2016 PRMT7 Preserves Satellite Cell Regenerative Capacity. Cell reports 71 26854227
2019 PRMT7 as a unique member of the protein arginine methyltransferase family: A review. Archives of biochemistry and biophysics 61 30802433
2022 Loss of PRMT7 reprograms glycine metabolism to selectively eradicate leukemia stem cells in CML. Cell metabolism 57 35508169
2021 Arginine monomethylation by PRMT7 controls MAVS-mediated antiviral innate immunity. Molecular cell 57 34171297
2016 A feedback loop comprising PRMT7 and miR-24-2 interplays with Oct4, Nanog, Klf4 and c-Myc to regulate stemness. Nucleic acids research 56 27625395
2022 PRMT7 ablation stimulates anti-tumor immunity and sensitizes melanoma to immune checkpoint blockade. Cell reports 54 35354055
2015 Histone Arginine Methylation by PRMT7 Controls Germinal Center Formation via Regulating Bcl6 Transcription. Journal of immunology (Baltimore, Md. : 1950) 54 26179907
2014 Substrate specificity of human protein arginine methyltransferase 7 (PRMT7): the importance of acidic residues in the double E loop. The Journal of biological chemistry 54 25294873
2018 PRMT7 contributes to the metastasis phenotype in human non-small-cell lung cancer cells possibly through the interaction with HSPA5 and EEF2. OncoTargets and therapy 46 30147338
2017 Apigenin enhances skeletal muscle hypertrophy and myoblast differentiation by regulating Prmt7. Oncotarget 42 29108230
2008 Protein arginine (N)-methyl transferase 7 (PRMT7) as a potential target for the sensitization of tumor cells to camptothecins. FEBS letters 40 18381071
2019 PRMT7 methylates eukaryotic translation initiation factor 2α and regulates its role in stress granule formation. Molecular biology of the cell 39 30699057
2016 Proteomic Analysis of Mouse Oocytes Identifies PRMT7 as a Reprogramming Factor that Replaces SOX2 in the Induction of Pluripotent Stem Cells. Journal of proteome research 36 27225728
2020 PRMT7 promotes the growth of renal cell carcinoma through modulating the β-catenin/C-MYC axis. The international journal of biochemistry & cell biology 35 31926310
2018 Expanding the clinical and molecular spectrum of PRMT7 mutations: 3 additional patients and review. Clinical genetics 35 28902392
2019 Zebrafish prmt7 negatively regulates antiviral responses by suppressing the retinoic acid-inducible gene-I-like receptor signaling. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 31 31914680
2019 Prmt7 promotes myoblast differentiation via methylation of p38MAPK on arginine residue 70. Cell death and differentiation 28 31243342
2016 Loss of the arginine methyltranserase PRMT7 causes syndromic intellectual disability with microcephaly and brachydactyly. Clinical genetics 27 27718516
2022 PRMT7 ablation in cardiomyocytes causes cardiac hypertrophy and fibrosis through β-catenin dysregulation. Cellular and molecular life sciences : CMLS 25 35089423
2019 PRMT7 methylates and suppresses GLI2 binding to SUFU thereby promoting its activation. Cell death and differentiation 25 31000813
2021 Structure and Function of Protein Arginine Methyltransferase PRMT7. Life (Basel, Switzerland) 24 34440512
2021 PRMT7 targets of Foxm1 controls alveolar myofibroblast proliferation and differentiation during alveologenesis. Cell death & disease 22 34497269
2020 PRMT7 regulates RNA-binding capacity and protein stability in Leishmania parasites. Nucleic acids research 20 32365184
2022 An enhancer variant at 16q22.1 predisposes to hepatocellular carcinoma via regulating PRMT7 expression. Nature communications 19 35264579
2020 Arginine methylation of SHANK2 by PRMT7 promotes human breast cancer metastasis through activating endosomal FAK signalling. eLife 19 32844749
2020 PRMT7 deficiency causes dysregulation of the HCN channels in the CA1 pyramidal cells and impairment of social behaviors. Experimental & molecular medicine 17 32269286
2023 PRMT7 Inhibits the Proliferation and Migration of Gastric Cancer Cells by Suppressing the PI3K/AKT Pathway via PTEN. Journal of Cancer 16 37781082
2019 PRMT7 deficiency enhances adipogenesis through modulation of C/EBP-β. Biochemical and biophysical research communications 16 31371025
2017 Caenorhabditis elegans PRMT-7 and PRMT-9 Are Evolutionarily Conserved Protein Arginine Methyltransferases with Distinct Substrate Specificities. Biochemistry 16 28441492
2018 Prenatal and postnatal presentation of PRMT7 related syndrome: Expanding the phenotypic manifestations. American journal of medical genetics. Part A 15 30513135
2024 METTL3/IGF2BP1 promotes the development of triple-negative breast cancer by mediating m6A methylation modification of PRMT7. Tissue & cell 14 39709713
2021 PRMT7: A Pivotal Arginine Methyltransferase in Stem Cells and Development. Stem cells international 14 34712331
2023 Identification of a Protein Arginine Methyltransferase 7 (PRMT7)/Protein Arginine Methyltransferase 9 (PRMT9) Inhibitor. Journal of medicinal chemistry 13 37560786
2021 Novel PRMT7 mutation in a rare case of dysmorphism and intellectual disability. Journal of human genetics 13 34244600
2021 The Effects of Flavonoid Apigenin on Male Reproductive Health: Inhibition of Spermatogonial Proliferation through Downregulation of Prmt7/Akt3 Pathway. International journal of molecular sciences 13 34830091
2018 Further delineation of the phenotype caused by loss of function mutations in PRMT7. European journal of medical genetics 13 30006058
2019 Transcriptome association studies of neuropsychiatric traits in African Americans implicate PRMT7 in schizophrenia. PeerJ 12 31579629
2022 Arginine Methyltransferase PRMT7 Deregulates Expression of RUNX1 Target Genes in T-Cell Acute Lymphoblastic Leukemia. Cancers 11 35565298
2022 Circ_0039960 regulates growth and Warburg effect of breast cancer cells via modulating miR-1178/PRMT7 axis. Molecular and cellular probes 11 35597500
2017 PRMT7 Interacts with ASS1 and Citrullinemia Mutations Disrupt the Interaction. Journal of molecular biology 11 28587924
2024 PRMT7-Dependent Transcriptional Activation of Hmgb2 Aggravates Severe Acute Pancreatitis by Promoting Acsl1-Induced Ferroptosis. Journal of proteome research 10 38376246
2022 Biallelic PRMT7 pathogenic variants are associated with a recognizable syndromic neurodevelopmental disorder with short stature, obesity, and craniofacial and digital abnormalities. Genetics in medicine : official journal of the American College of Medical Genetics 10 36399134
2020 PRMT7 is involved in regulation of germ cell proliferation during embryonic stage. Biochemical and biophysical research communications 10 33008598
2024 Prmt7 regulates the JAK/STAT/Socs3 signaling pathway in postmenopausal cardiomyopathy. Experimental & molecular medicine 9 38486105
2023 PRMT7 can prevent neurovascular uncoupling, blood-brain barrier permeability, and mitochondrial dysfunction in repetitive and mild traumatic brain injury. Experimental neurology 9 37196697
2023 Structures of SARS-CoV-2 N7-methyltransferase with DOT1L and PRMT7 inhibitors provide a platform for new antivirals. PLoS pathogens 8 37523415
2022 PRMT7 Inhibitor SGC8158 Enhances Doxorubicin-Induced DNA Damage and Its Cytotoxicity. International journal of molecular sciences 8 36293180
2019 Examining Product Specificity in Protein Arginine Methyltransferase 7 (PRMT7) Using Quantum and Molecular Mechanical Simulations. Journal of chemical information and modeling 8 31033288
2013 Prmt7 is dispensable in tissue culture models for adipogenic differentiation. F1000Research 8 24715966
2018 Prmt7 regulates epiboly and gastrulation cell movements by facilitating syntenin. Acta biochimica et biophysica Sinica 7 30383201
2024 PRMT-7/PRMT7 activates HLH-30/TFEB to guard plasma membrane integrity compromised by bacterial pore-forming toxins. Autophagy 6 38261662
2022 Short stature in PRMT7 Mutations: first evidence of response to growth hormone treatment. European journal of human genetics : EJHG 6 36348013
2024 PRMT7 in cancer: Structure, effects, and therapeutic potentials. European journal of medicinal chemistry 5 39615371
2024 Prmt7 is required for the osteogenic differentiation of mesenchymal stem cells via modulation of BMP signaling. BMB reports 4 38627951
2024 Targeting PRMT7-mediated monomethylation of MAVS enhances antiviral innate immune responses and inhibits RNA virus replication. Proceedings of the National Academy of Sciences of the United States of America 4 39546576
2023 The exquisite specificity of human protein arginine methyltransferase 7 (PRMT7) toward Arg-X-Arg sites. PloS one 4 37216364
2020 Catalytic Mechanism and Product Specificity of Protein Arginine Methyltransferase PRMT7: A Study from QM/MM Molecular Dynamics and Free Energy Simulations. Journal of chemical theory and computation 4 32585103
2025 Endothelial PRMT7 prevents dysfunction, promotes revascularization and enhances cardiac recovery post-myocardial infarction. Experimental & molecular medicine 3 40764455
2025 Development of Novel PRMT7 Inhibitors for the Treatment of Prostate Cancer. Journal of medicinal chemistry 2 40223545
2022 Unraveling the Origins of Changing Product Specificity Properties of Arginine Methyltransferase PRMT7 by the E181D and E181D/Q329A Mutations through QM/MM MD and Free-Energy Simulations. Journal of chemical theory and computation 2 35316052
2020 Identification, expression and functional analysis of prmt7 in medaka Oryzias latipes. Journal of experimental zoology. Part B, Molecular and developmental evolution 2 31990140
2025 PRMT7-Mediated PTEN Activation Enhances Bone Regeneration in Female Mice. International journal of molecular sciences 1 40243588
2024 Methylation and phosphorylation of formin homology domain proteins (Fhod1 and Fhod3) by protein arginine methyltransferase 7 (PRMT7) and Rho kinase (ROCK1). The Journal of biological chemistry 1 39368550
2022 Prmt7 Downregulation in Mouse Spermatogonia Functions through miR-877-3p/Col6a3. Life (Basel, Switzerland) 1 36013373
2026 CRISPR screens identify PRMT7 as a therapeutic target to enhance T cell-mediated killing in breast cancer. NPJ breast cancer 0 41565695
2026 AKT1 phosphorylates PRMT7 to promote GLUD1 methylation and gastric cancer progression. Cell death & disease 0 41876450
2026 Tailoring PRMT Inhibition: Shifting PRMT7 Selectivity to PRMT4 through "T-Shape" Strategy and "Linker-Specific" Preferences. Journal of medicinal chemistry 0 42066234
2025 PRMT7 Inhibitor SGC3027 Enhances Radiotherapy Efficacy via Activating ATM Kinase in Non-Small Cell Lung Carcinoma. Radiation research 0 40015317

Missed literature

Know a paper Affinage missed for PRMT7? Flag it for the maintainers and the community.

No submissions yet.